Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It is approved for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
Lead Product(s): Vadadustat
Therapeutic Area: Nephrology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Vadadustat is currently approved for use in 35 countries.
Lead Product(s): Vadadustat
Therapeutic Area: Nephrology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. Vadadustat is currently approved for use in 34 countries.
Lead Product(s): Vadadustat
Therapeutic Area: Hematology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. Vadadustat is currently approved for use in 34 countries.
Lead Product(s): Vadadustat
Therapeutic Area: Hematology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. It is being developed for the treating symptomatic anaemia associated with CKD.
Lead Product(s): Vadadustat
Therapeutic Area: Hematology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, approved for use in 33 countries for the treatment of symptomatic anemia associated with CKD, received a written response from FDA stating denial of formal dispute resolution regarding the CRL.
Lead Product(s): Vadadustat
Therapeutic Area: Hematology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
Under the agreement, Medice to market Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor developed by Akebia to treat anemia due to chronic kidney disease (CKD), in Europe.
Lead Product(s): Vadadustat
Therapeutic Area: Nephrology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medice Arzneimittel Pütter GmbH&Co.KG
Deal Size: $110.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement May 25, 2023
Details:
Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. It is being developed for the treating symptomatic anaemia associated with CKD.
Lead Product(s): Vadadustat
Therapeutic Area: Hematology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. It is being developed for the treating symptomatic anaemia associated with CKD.
Lead Product(s): Vadadustat
Therapeutic Area: Hematology Product Name: Vafseo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
The data demonstrated that Vafseo, having vadadustat met the primary and secondary efficacy endpoints and was non-inferior to an ESA in the treatment of anemia due to chronic kidney disease in patients on hemodialysis.
Lead Product(s): Vadadustat
Therapeutic Area: Hematology Product Name: Vafseo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023